Manipulating Human Cell Genetics for Cellular Therapies

Comprehensive genetic manipulation of cellular therapies The Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells. The lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions. This webinar presents the Roth Lab's development of CRISPR-All, a versatile genetic perturbation platform for primary human cells. It explores how this technology enables the engineering of synthetic cell states with therapeutic potential by pushing human genetics beyond natural evolutionary limits. CRISPR-All is a versatile genetic perturbation platform for primary human cells developed by the Roth lab that enables flexible, large-scale genetic editing in primary human cells. In this webinar, Dr. Theo Roth will discuss how CRISPR-All can be used to push human genetics beyond their evolved functionality, enabling researchers to engineer synthetic cell states with therapeutic potential. He will explore how tailoring human genes to specific cells and specific environments can drive previously inaccessible therapeutic cellular functions, discussing what this means for the future of cell-based therapies. How synthetic genes can be integrated specifically at endogenous genes to engineer T-cell specificity About the benefits of pooled screening systems for cell engineering How pooled genetic perturbations can be combined with high-dimensional single-cell phenotypes Theo Roth completed his MD and PhD training at the University of California, San Francisco and his clinical residency in Pathology at Stanford University, and recently began as an Assistant Professor in the Department of Pathology at Stanford University. He holds a Burroughs Wellcome Fund Career Award for Medical Scientists, is an Innovation Investigator of the Arc Institute, and a Senior Fellow of the Parker Institute for Cancer Immunotherapy, in addition to support from the NIH-NCI and The Cancer League. His research focuses on the development, application, and translation of scalable technologies for the genetic manipulation of primary human cells. Theo’s past work on non-viral genome targeting and pooled knockin screening in human T cells have led to multiple active clinical trials in academics and industry, and he was the founding CSO and scientific co-founder of Arsenal Biosciences.